|
|
|
The Monash Antibody Technologies Facility was established to provide national and international Life Science researchers custom-made, high-affinity monoclonal antibodies and support services. In a very short period of time, MATF has become one of the only truly high volume production facilities in the world offering custom-made, high affinity monoclonal antibodies.
The MATF will strive to:
-
Produce thousands of high quality, high affinity monoclonal antibodies annually
-
Invest human and resource capital into new proteomics technologies
-
Become an integral part of the efforts to improve the human condition by generating novel, powerful
bio-medical tools
|
